These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 23647607

  • 1. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [Abstract] [Full Text] [Related]

  • 2. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Cabrera N, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM, Rendo P, Smith L, Altisent C.
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE.
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
    Quon DV, Logan L.
    Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [Abstract] [Full Text] [Related]

  • 15. The features of clearance in recombinant factor IX (BeneFIX(®) ).
    Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T.
    Haemophilia; 2015 Sep; 21(5):702-7. PubMed ID: 25854709
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
    Chang HH, Yang YL, Hung MH, Tsay W, Shen MC.
    J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
    [Abstract] [Full Text] [Related]

  • 17. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF, B-LONG Investigators.
    N Engl J Med; 2013 Dec 12; 369(24):2313-23. PubMed ID: 24304002
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug 12; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.